Tonix Pharmaceuticals (NASDAQ:TNXP) Downgraded by Wall Street Zen to Sell

Tonix Pharmaceuticals (NASDAQ:TNXP) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold”.

Tonix Pharmaceuticals Stock Performance

Shares of TNXP stock opened at $12.88 on Friday. The stock’s 50 day simple moving average is $15.42 and its 200 day simple moving average is $18.03. Tonix Pharmaceuticals has a twelve month low of $12.70 and a twelve month high of $69.97. The company has a market capitalization of $172.59 million, a price-to-earnings ratio of -0.90 and a beta of 1.88.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its earnings results on Thursday, March 12th. The company reported ($3.98) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.16) by ($0.82). Tonix Pharmaceuticals had a negative return on equity of 60.15% and a negative net margin of 946.22%.The company had revenue of $5.39 million for the quarter, compared to the consensus estimate of $2.97 million. On average, analysts forecast that Tonix Pharmaceuticals will post -1762.5 EPS for the current fiscal year.

Insider Buying and Selling at Tonix Pharmaceuticals

In other Tonix Pharmaceuticals news, CEO Seth Lederman bought 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 18th. The stock was purchased at an average price of $14.89 per share, for a total transaction of $223,350.00. Following the purchase, the chief executive officer directly owned 15,001 shares in the company, valued at $223,364.89. This trade represents a 1,500,000.00% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.03% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Legal & General Group Plc acquired a new position in shares of Tonix Pharmaceuticals during the second quarter worth approximately $25,000. Ameritas Investment Partners Inc. acquired a new stake in shares of Tonix Pharmaceuticals in the second quarter worth $28,000. Russell Investments Group Ltd. acquired a new stake in shares of Tonix Pharmaceuticals in the third quarter worth $29,000. Police & Firemen s Retirement System of New Jersey bought a new position in Tonix Pharmaceuticals during the second quarter worth $62,000. Finally, State of Wyoming bought a new position in Tonix Pharmaceuticals during the fourth quarter worth $27,000. 82.26% of the stock is owned by institutional investors.

Tonix Pharmaceuticals News Roundup

Here are the key news stories impacting Tonix Pharmaceuticals this week:

• Positive Sentiment: First participant dosed in a Phase 1 investigator‑initiated pharmacodynamic study of TNX‑1900 to assess potential for treating migraine and craniofacial pain; intranasal oxytocin blocks CGRP release in animal models and represents a mechanism distinct from current CGRP drugs, which could broaden Tonix’s pipeline if signals are positive. Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900
• Neutral Sentiment: Multiple outlets (Business Insider, Yahoo Finance, TipRanks) picked up the dosing announcement — that raises visibility and investor attention but the study is early‑stage (pharmacodynamic model), so clinical readouts and commercialization remain uncertain. Tonix Pharmaceuticals Announces First Participant Dosed (Business Insider)
• Negative Sentiment: Zacks Research substantially lowered its near‑term EPS forecasts for Tonix, cutting FY2026 and FY2027 estimates and issuing much larger expected losses per share (e.g., FY2026 now modeled at roughly -$10.52). Those revisions signal analyst concern about cash runway, development timelines and the likelihood of future dilution — a key reason for downward pressure on the stock. What is Zacks Research’s Estimate for TNXP FY2028 Earnings?

About Tonix Pharmaceuticals

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.